Modular "Vant" Structure for Focus and Agility: Roivant's unique model of creating independent subsidiary companies ("Vants") allows dedicated teams and resources to focus intensely on specific drug candidates or therapeutic areas, fostering agility and potentially more efficient capital deployment compared to traditional large pharmaceutical structures.

Strategic Acquisition of Under-Appreciated Assets: The company specializes in identifying and acquiring or in-licensing promising late-stage drug candidates that have been deprioritized, shelved, or undervalued by larger pharmaceutical companies, unlocking their untapped potential.

Data-Driven Development Optimization: Roivant employs advanced data science and artificial intelligence methodologies to enhance various stages of drug development, including optimizing clinical trial design, patient selection, and identifying development efficiencies.